Acute Hypoxemic Respiratory Failure in Immunocompromised Patients: the Efraim Multinational Prospective Cohort Study

Background: In immunocompromised patients with acute hypoxemic respiratory failure (ARF), initial management aims primarily to avoid invasive mechanical ventilation (IMV).

Methods: To assess the impact of initial management on IMV and mortality rates, we performed a multinational observational prospective cohort study in 16 countries (68 centers).

Results: A total of 1611 patients were enrolled (hematological malignancies 51.9%, solid tumors 35.2%, systemic diseases 17.3%, and solid organ transplantation 8.8%). The main ARF etiologies were bacterial (29.5%), viral (15.4%), and fungal infections (14.7%), or undetermined (13.2%). On admission, 915 (56.8%) patients were not intubated. They received standard oxygen (N = 496, 53.9%), high-flow oxygen (HFNC, N = 187, 20.3%), noninvasive ventilation (NIV, N = 153, 17.2%), and NIV + HFNC (N = 79, 8.6%). Factors associated with IMV included age (hazard ratio = 0.92/year, 95% CI 0.86-0.99), day-1 SOFA (1.09/point, 1.06-1.13), day-1 PaO/FiO (1.47, 1.05-2.07), ARF etiology (Pneumocystis jirovecii pneumonia (2.11, 1.42-3.14), invasive pulmonary aspergillosis (1.85, 1.21-2.85), and undetermined cause (1.46, 1.09-1.98). After propensity score matching, HFNC, but not NIV, had an effect on IMV rate (HR = 0.77, 95% CI 0.59-1.00, p = 0.05). ICU, hospital, and day-90 mortality rates were 32.4, 44.1, and 56.4%, respectively. Factors independently associated with hospital mortality included age (odds ratio = 1.18/year, 1.09-1.27), direct admission to the ICU (0.69, 0.54-0.87), day-1 SOFA excluding respiratory score (1.12/point, 1.08-1.16), PaO/FiO < 100 (1.60, 1.03-2.48), and undetermined ARF etiology (1.43, 1.04-1.97). Initial oxygenation strategy did not affect mortality; however, IMV was associated with mortality, the odds ratio depending on IMV conditions: NIV + HFNC failure (2.31, 1.09-4.91), first-line IMV (2.55, 1.94-3.29), NIV failure (3.65, 2.05-6.53), standard oxygen failure (4.16, 2.91-5.93), and HFNC failure (5.54, 3.27-9.38).

Conclusion: HFNC has an effect on intubation but not on mortality rates. Failure to identify ARF etiology is associated with higher rates of both intubation and mortality. This suggests that in addition to selecting the appropriate oxygenation device, clinicians should strive to identify the etiology of ARF.

Citing Articles

A Systematic Literature Review to Determine Gaps in Diagnosing Suspected Infection in Solid Organ Transplant Recipients.

Park S, Goldman J, Levine D, Haidar G Open Forum Infect Dis. 2025; 12(1):ofaf001.

PMID: 39877399 PMC: 11773193. DOI: 10.1093/ofid/ofaf001.

Previous treatment with anthracycline does not affect the course of sepsis in cancer patients: Retrospective cohort study.

Windsor C, Joseph A, Pons S, Mokart D, Pene F, Kouatchet A J Intensive Med. 2025; 5(1):64-69.

PMID: 39872834 PMC: 11763860. DOI: 10.1016/j.jointm.2024.07.005.

Diagnostic performance of the DISQVER metagenomic sequencing tool for the identification of pathogens in febrile neutropenic patients: the ADNEMIA trial.

Pichon M, Burucoa C BMJ Open. 2025; 15(1):e087773.

PMID: 39843376 PMC: 11784336. DOI: 10.1136/bmjopen-2024-087773.

What intensivists need to know about cytomegalovirus infection in immunocompromised ICU patients.

Fernandez S, Castro P, Azoulay E Intensive Care Med. 2025; 51(1):39-61.

PMID: 39774866 DOI: 10.1007/s00134-024-07737-5.

Prognostic indicators in intensive care unit oncology patients: bridging short-term and long-term survival.

Atallah F, Rosa R, Puxty K Crit Care Sci. 2024; 36:e20240262en.

PMID: 39699392 PMC: 11634240. DOI: 10.62675/2965-2774.20240262-en.

References

Mokart D, Lambert J, Schnell D, Fouche L, Rabbat A, Kouatchet A . Delayed intensive care unit admission is associated with increased mortality in patients with cancer with acute respiratory failure. Leuk Lymphoma. 2012; 54(8):1724-9. DOI: 10.3109/10428194.2012.753446. View

Azoulay E, Pene F, Darmon M, Lengline E, Benoit D, Soares M . Managing critically Ill hematology patients: Time to think differently. Blood Rev. 2015; 29(6):359-67. DOI: 10.1016/j.blre.2015.04.002. View

Azoulay E, Mokart D, Lambert J, Lemiale V, Rabbat A, Kouatchet A . Diagnostic strategy for hematology and oncology patients with acute respiratory failure: randomized controlled trial. Am J Respir Crit Care Med. 2010; 182(8):1038-46. DOI: 10.1164/rccm.201001-0018OC. View

Contejean A, Lemiale V, Resche-Rigon M, Mokart D, Pene F, Kouatchet A . Increased mortality in hematological malignancy patients with acute respiratory failure from undetermined etiology: a Groupe de Recherche en Réanimation Respiratoire en Onco-Hématologique (Grrr-OH) study. Ann Intensive Care. 2016; 6(1):102. PMC: 5080277. DOI: 10.1186/s13613-016-0202-0. View

Puxty K, McLoone P, Quasim T, Sloan B, Kinsella J, Morrison D . Risk of Critical Illness Among Patients With Solid Cancers: A Population-Based Observational Study. JAMA Oncol. 2015; 1(8):1078-85. DOI: 10.1001/jamaoncol.2015.2855. View

Antonelli M, Conti G, Rocco M, Bufi M, De Blasi R, Vivino G . A comparison of noninvasive positive-pressure ventilation and conventional mechanical ventilation in patients with acute respiratory failure. N Engl J Med. 1998; 339(7):429-35. DOI: 10.1056/NEJM199808133390703. View

Morrison V . Immunosuppression associated with novel chemotherapy agents and monoclonal antibodies. Clin Infect Dis. 2014; 59 Suppl 5:S360-4. DOI: 10.1093/cid/ciu592. View

Rano A, Agusti C, Benito N, Rovira M, Angrill J, Pumarola T . Prognostic factors of non-HIV immunocompromised patients with pulmonary infiltrates. Chest. 2002; 122(1):253-61. DOI: 10.1378/chest.122.1.253. View

Lemiale V, Mokart D, Resche-Rigon M, Pene F, Mayaux J, Faucher E . Effect of Noninvasive Ventilation vs Oxygen Therapy on Mortality Among Immunocompromised Patients With Acute Respiratory Failure: A Randomized Clinical Trial. JAMA. 2015; 314(16):1711-9. DOI: 10.1001/jama.2015.12402. View

10.

Siegel R, Miller K, Jemal A . Cancer Statistics, 2017. CA Cancer J Clin. 2017; 67(1):7-30. DOI: 10.3322/caac.21387. View

11.

Lemiale V, Resche-Rigon M, Mokart D, Pene F, Argaud L, Mayaux J . High-Flow Nasal Cannula Oxygenation in Immunocompromised Patients With Acute Hypoxemic Respiratory Failure: A Groupe de Recherche Respiratoire en Réanimation Onco-Hématologique Study. Crit Care Med. 2016; 45(3):e274-e280. DOI: 10.1097/CCM.0000000000002085. View

12.

Frat J, Ragot S, Girault C, Perbet S, Prat G, Boulain T . Effect of non-invasive oxygenation strategies in immunocompromised patients with severe acute respiratory failure: a post-hoc analysis of a randomised trial. Lancet Respir Med. 2016; 4(8):646-652. DOI: 10.1016/S2213-2600(16)30093-5. View

13.

Harpaz R, Dahl R, Dooling K . Prevalence of Immunosuppression Among US Adults, 2013. JAMA. 2016; 316(23):2547-2548. DOI: 10.1001/jama.2016.16477. View

14.

Azoulay E, Lemiale V, Mokart D, Pene F, Kouatchet A, Perez P . Acute respiratory distress syndrome in patients with malignancies. Intensive Care Med. 2014; 40(8):1106-14. DOI: 10.1007/s00134-014-3354-0. View

15.

Novosad S, Winthrop K . Beyond tumor necrosis factor inhibition: the expanding pipeline of biologic therapies for inflammatory diseases and their associated infectious sequelae. Clin Infect Dis. 2014; 58(11):1587-98. DOI: 10.1093/cid/ciu104. View

16.

Azoulay E, Mokart D, Pene F, Lambert J, Kouatchet A, Mayaux J . Outcomes of critically ill patients with hematologic malignancies: prospective multicenter data from France and Belgium--a groupe de recherche respiratoire en réanimation onco-hématologique study. J Clin Oncol. 2013; 31(22):2810-8. DOI: 10.1200/JCO.2012.47.2365. View

17.

Hilbert G, Gruson D, Vargas F, Valentino R, Gbikpi-Benissan G, Dupon M . Noninvasive ventilation in immunosuppressed patients with pulmonary infiltrates, fever, and acute respiratory failure. N Engl J Med. 2001; 344(7):481-7. DOI: 10.1056/NEJM200102153440703. View

18.

Gristina G, Antonelli M, Conti G, Ciarlone A, Rogante S, Rossi C . Noninvasive versus invasive ventilation for acute respiratory failure in patients with hematologic malignancies: a 5-year multicenter observational survey. Crit Care Med. 2011; 39(10):2232-9. DOI: 10.1097/CCM.0b013e3182227a27. View

19.

Winthrop K, Novosad S, Baddley J, Calabrese L, Chiller T, Polgreen P . Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance. Ann Rheum Dis. 2015; 74(12):2107-16. DOI: 10.1136/annrheumdis-2015-207841. View

20.

Mokart D, Geay C, Chow-Chine L, Brun J, Faucher M, Blache J . High-flow oxygen therapy in cancer patients with acute respiratory failure. Intensive Care Med. 2015; 41(11):2008-10. DOI: 10.1007/s00134-015-3994-8. View